title: A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
abstract: OBJECTIVE
  This study aimed at evaluating the efficacy and safety of epirubicin, oxaliplatin, and capecitabine (EOX) in advanced gastric cancer (AGC) patients in the Chinese population.
  
  
  METHODS
  Patients with previously untreated advanced measurable gastric cancer received epirubicin (50 mg/m(2), day 1), oxaliplatin (130 mg/m(2) 2-hour infusion, day 1) and capecitabine (625 mg/m(2) orally, twice daily, days 1-21) every 3 weeks.
  
  
  RESULTS
  Of 48 enrolled patients, 47 were evaluable for efficacy and 48 for toxicity. A median of five cycles (range 1-8) was administered. The overall response rate was 51.1% (95% CI 36-66) with two complete responses, 22 partial responses, 16 stable diseases, and 7 progressions. Median progression-free survival was 6.5 months (95% CI 5.6-7.4) and median overall survival was 10.4 months (95% CI 8.8-12.0). Grade 3-4 neutropenia and anemia were observed in 22.9 and 6.3% of patients, respectively. Grade 3-4 nonhematological toxicities included alopecia (18.9%), nausea (8.3%), vomiting (6.3%), diarrhea (6.3%), hand-foot syndrome (4.2%) and neurological toxicity (2.1%).
  
  
  CONCLUSIONS
  In our experience, the EOX regimen was highly effective, well tolerated and conveniently delivered as first-line chemotherapy for AGC patients in the Chinese population.
authors.affiliation: Department of Oncology, The First Affiliated Hospital, Nanchang University, Nanchang, China.
authors.forename: Xiao Jun
authors.initials: XJ
authors.lastname: Xiang
authors.forename: Feng
authors.initials: F
authors.lastname: Qiu
authors.forename: Jian Ping
authors.initials: JP
authors.lastname: Xiong
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: Yu
authors.forename: Miao
authors.initials: M
authors.lastname: Feng
authors.forename: Zheng Yu
authors.initials: ZY
authors.lastname: Zhan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D044466:Asian People / Q000208:ethnology*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000208:ethnology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000208:ethnology* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D015251:Epirubicin; D000069287:Capecitabine; D005472:Fluorouracil